Medical device testing market seen topping $28 billion by 2035

The global medical device testing services market is projected to grow from $11.80 billion in 2026 to $28.05 billion by 2035, according to Market Research Future. Stricter FDA cybersecurity rules, EU MDR recertification pressure and rising demand for connected and AI-enabled devices are expected to keep testing demand elevated. Why it matters: - Medical device testing has become a compliance bottleneck, not a discretionary spend. - The market’s growth reflects mandatory pre-market and post-market requirements for connected devices, higher-risk products and legacy devices moving through re-certification. - Faster testing demand can speed or slow device launches, depending on lab capacity and regulatory timelines. What happened: - Market Research Future said the global Medical Device Testing Services Market will grow from USD 11.80 billion in 2026 to USD 28.05 billion by 2035. - The forecast implies a 10.1% compound annual growth rate from 2026 to 2035. - The market base was estimated at USD 10.72 billion in 2025. - The estimate was published June 19, 2026. - The report points to FDA cybersecurity rules, EU MDR transition deadlines and growth in connected wearables and AI-enabled implantables as the main drivers. The details: - The FDA’s 2023 cybersecurity guidance requires software bill of materials and threat-model documentation for pre-market submissions involving connected functionality. - By early 2026, the FDA had authorized more than 1,350 AI-enabled medical devices. - The EU MDR’s Article 120 timeline forced an estimated 23,000 legacy devices through full re-certification by May 2024. - Medtech Europe reported a 42% shortfall in notified-body audit capacity in Q1 2025. - Biocompatibility testing was the largest service segment in 2024, with about 32.0% revenue share. - Electrical safety and EMC testing is forecast to grow fastest among service types, at 14.5% CAGR through 2035. - Pre-clinical testing held about 47.5% revenue share in 2024. - Post-market surveillance testing is expected to grow fastest among development phases, at 13.8% CAGR through 2035. - Class II devices accounted for about 55.0% of revenue in 2024. - Class III devices are projected to be the fastest-growing device class, at 14.8% CAGR through 2035. - Medical device OEMs held about 61.0% of revenue in 2024. - Contract research organizations are projected to be the fastest-growing end-user segment, at 12.8% CAGR through 2035. - North America led the market in 2024 with about 39.2% share. - The U.S. generated about 82.3% of North American revenue. - Europe ranked second with about 26.5% share in 2024. - Asia-Pacific is projected to be the fastest-growing region, at 13.0% CAGR through 2035. - China held about 34.6% of Asia-Pacific revenue. - Middle East and Africa accounted for 5.7% of the market in 2024. - South America was valued at USD 0.62 billion in 2025. - SGS SA and Bureau Veritas were highlighted among the leading players. - The top five companies held an estimated 32% to 36% combined revenue share. - The market’s Herfindahl-Hirschman Index was estimated at 600 to 900, pointing to moderate fragmentation. - The report says top-five concentration could rise above 40% by 2030 as mergers and scale economics favor larger lab networks. - The report’s future outlook says AI-integrated testing workflows and in-silico tools could reshape validation by 2030. - It also says machine-learning models could reduce animal-study requirements by 30% to 40% for qualifying materials by 2030. - Robotic sample handling and machine-learning anomaly detection could raise lab throughput by 40% to 50%. Between the lines: - The strongest demand is coming from regulation, not from broad healthcare spending cycles. - Large testing networks appear positioned to benefit most because they can cover multiple jurisdictions, accreditations and specialties at once. - Outsourcing pressure is rising as manufacturers avoid the cost of maintaining their own ISO 17025-accredited labs. - The report suggests post-market testing will become more important as regulators extend oversight beyond initial clearance. What’s next: - Testing labs are likely to see continued demand from FDA cybersecurity filings, MDR recertification work and connected-device launches. - Manufacturers are expected to lean more on third-party labs and CROs as compliance requirements widen. - Investment in automation and AI-driven workflows may become a competitive advantage for labs chasing higher throughput and shorter turnaround times. - The report links to the full market report and offers a free sample request .